CHARM Therapeutics
London
About CHARM Therapeutics
Charm Therapeutics designs and develops a new generation of small-molecule therapeutics that target the interaction between menin and the KMT2A protein, a key driver of acute myeloid leukemia (AML), using its proprietary AI-powered platform called DragonFold. The company’s lead program is a menin inhibitor optimized to maintain activity against all known clinical resistance mutations while minimizing safety and drug-interaction risks. Charm Therapeutics employs protein-ligand co-folding intelligence to inform molecular design, advancing its pipeline from preclinical stages toward the clinic.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $162.7M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2025)
- Website: charmtx.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/charm-therapeutics-59521 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.